Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The physical effects of etizolam can be broken down into several components which progressively intensify proportional to dosage.
The cognitive effects of etizolam can be broken down into several components which progressively intensify proportional to dosage. The general head space of etizolam is described by many as one of recreationally intense sedation and decreased inhibition. It contains a large number of typical depressant cognitive effects.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Etizolam is considered highly addictive with significant abuse potential. Compulsive redosing is commonly reported, particularly during states of reduced inhibition, and many users struggle with long-term addiction that is extremely difficult to overcome.
Physical dependence develops with regular use, and discontinuation can be dangerous or even life-threatening for heavy or long-term users. Withdrawal symptoms include dizziness, physical weakness, inner restlessness, tremors, sleep disturbances, headaches, sweating, nausea, hallucinations, and depression. Some studies suggest etizolam may have reduced liability to induce dependence compared to classic benzodiazepines, though significant risk remains.
The LD50 of etizolam is currently unknown. Etizolam has been reported to have a lower LD50 than certain benzodiazepines, suggesting higher toxicity. While etizolam likely has low toxicity relative to dose when used alone, overdose deaths have been documented, particularly in combination with other GABAergic substances. Overdose deaths have been rising significantly in some regions.
Long-term use may result in blepharospasms (involuntary eyelid muscle contractions), with this effect appearing more frequently in women and those with chronic abuse patterns.
In rare cases, etizolam abuse has been associated with erythema annulare centrifugum skin lesions.
Long-term use has been associated with adverse effects on cognitive function, including memory impairment, as well as emotional and social dissociation or derealization; doses of 4 mg or more may cause anterograde amnesia acutely.
Hallucinations and delusions are rare but may occur during severe overdose or as part of withdrawal syndrome. Long-term use has been associated with derealization. Paradoxical reactions including aggression, violent behavior, and loss of impulse control occur rarely, with an incidence rate below 1% in the general population, though more frequently in recreational abusers, individuals with mental disorders, and those on high-dosage regimes.
Etizolam itself has anticonvulsant properties; however, there is an increased risk of seizures following abrupt discontinuation, particularly in long-term or heavy users. Paradoxical increases in seizure activity may occur in epileptics. Gradual tapering is essential to minimize withdrawal seizure risk, and substances that lower the seizure threshold should be avoided during discontinuation.
Etizolam was patented in 1972 and first received approval for medical use in Japan in 1984. Medical literature documenting its therapeutic application for anxiety conditions has appeared since at least the early 1990s. The compound has been prescribed as an anxiolytic in several countries, commonly
UN Convention on Psychotropic Substances (Schedule IV, March 2020)
Listed as Schedule 4 by the Office of Drug Control under Regulation 5 of the Customs (Prohibited Imports) Regulations 1956. License and permit required for import and export.
Illegal since March 23, 2021 following ANVISA Resolution RDC nº 473. Listed on Portaria SVS/MS nº 344, prohibiting possession, production, and sale.
Classified as a controlled drug since 2016. Not approved for medical use in Finland.
Regulated under the Narcotics and Psychotropics Control Law. Possession, sale, and manufacture without a prescription are illegal. Approved for medical use with prescription.
Classified as a New Psychoactive Substance under the Act on Counteracting Drug Addiction. Possession and distribution are prohibited.
Specifically named as a controlled substance under Verzeichnis B of Swiss narcotics legislation. Medicinal use is permitted with appropriate authorization.
Controlled as a Class C substance under the Misuse of Drugs Act 1971 since May 31, 2017. Possession, production, and supply are criminal offenses.
Prohibited since 2012 under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act). Possession, production, supply, and import are illegal, though offenders without intent to distribute may not face prosecution.
Captured under section 18 of Schedule VI of the Controlled Drugs and Substances Act as a benzodiazepine derivative and its salts.
Controlled under Anlage III of the Betäubungsmittelgesetz (Narcotics Act) since July 17, 2013. Can only be prescribed using a narcotic prescription form (Betäubungsmittelrezept).
Controlled as a List 2 substance under the Opium Act (Opiumwet). Possession and distribution are illegal.
Listed as a Schedule III controlled substance since 2017 under Russian drug control legislation.
Classified as a controlled drug under Turkish law. Possession, production, supply, and import are prohibited.
Temporarily placed in Schedule I by the DEA effective January 23, 2023, with permanent scheduling likely. Prior to federal action, numerous states independently scheduled etizolam: Alabama (Schedule I, March 2014), Mississippi (Schedule I, April 2014), Arkansas (Schedule I, December 2014), Georgia (Schedule IV, May 2015), Indiana (Schedule I, July 2017), North Carolina (Schedule I, March 2017), Texas (Penalty Group 3, June 2017), Arizona (controlled via House Bill 2033, 2018), and Florida, Louisiana, Ohio, South Carolina, and Virginia (various state controls).
19 sources cited
